Trinity Biotech Plc ADR (NASDAQ:TRIB)’s traded shares stood at 0.42 million during the latest session, with the company’s beta value hitting 1.20. At the last check today, the stock’s price was $2.03, to imply an increase of 10.93% or $0.2 in intraday trading. The TRIB share’s 52-week high remains $3.55, putting it -74.88% down since that peak but still an impressive 48.28% since price per share fell to its 52-week low of $1.05. The company has a valuation of $23.08M, with an average of 0.22 million shares in intraday trading volume over the past 10 days and average of 1.32 million shares over the past 3 months.
Trinity Biotech Plc ADR (NASDAQ:TRIB) trade information
After registering a 10.93% upside in the latest session, Trinity Biotech Plc ADR (TRIB) has traded red over the past five days. The 5-day price performance for the stock is 18.71%, and 76.52% over 30 days. With these gigs, the year-to-date price performance is -5.36%. Short interest in Trinity Biotech Plc ADR (NASDAQ:TRIB) saw shorts transact 0.1 million shares and set a 0.4 days time to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Trinity Biotech Plc ADR (TRIB) estimates and forecasts
Looking at statistics comparing Trinity Biotech Plc ADR share performance against respective industry, we note that the company has outperformed competitors. Trinity Biotech Plc ADR (TRIB) shares are 10.93% up over the last 6 months, with its year-to-date growth rate higher than industry average at 37.39% against 11.50%. Revenue is forecast to grow 59.10% this quarter before jumping 38.20% for the next one. The rating firms project that company’s revenue will grow 15.30% compared to the previous financial year.
Revenue forecast for the current quarter as set by 1 analysts is 16.5M. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 18.5M.Earnings reports from the last fiscal year show that sales brought in 14.68M and 13.43M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 12.40% before jumping 37.80% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 9.90% for the past 5-year period. While 2024 is set for a 56.19% return in earnings, projections for the next 5 years are at 15.00% annually.
TRIB Dividends
Trinity Biotech Plc ADR has its next earnings report out on 2024-Aug-14. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. The company’s average dividend yield trailing the past 5-year period is 1.19%.
